US 7,320,785 B2 | ||
Compositions and methods for modulation of DARPP-32 phosphorylation | ||
Paul Greengard, New York, N.Y. (US); Per Svenningsson, New York, N.Y. (US); Sergey V. Rakhilin, Yorktown, N.Y. (US); and Natalia Starkova, New York, N.Y. (US) | ||
Assigned to The Rockefeller University, New York, N.Y. (US) | ||
Filed on Aug. 12, 2002, as Appl. No. 10/218,137. | ||
Claims priority of provisional application 60/311641, filed on Aug. 10, 2001. | ||
Prior Publication US 2003/0171255 A1, Sep. 11, 2003 | ||
Int. Cl. A61K 49/00 (2006.01); G01N 33/53 (2006.01); G01N 33/567 (2006.01) |
U.S. Cl. 424—9.2 [424/9.1; 435/7.2; 435/7.21] | 4 Claims |
1. A method for identifying an agent for use in treating depression in a patient in need thereof, comprising:
(a) contacting an agent with phosphatase 2C (“PP2C”) and Ser137-phosphorylated Dopamine- and cyclic-AMP-Regulated PhosphoProtein
of molecular weight 32,000 Dalton (“DARPP-32”);
(b) detecting the amount of dephosphorylation of Ser137-phosphorylated DARPP-32; and
(c) testing the agent in an animal model of depression, wherein the agent is identified as an agent for use in treating depression if a decrease in the dephosphorylation of Ser137-phosphorylated
DARPP-32 is detected in the presence of the agent in step (b) and if the agent is effective in the animal model tested in
step (c).
|